Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
5 min read
CytoDel LLC Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CytoDel LLC, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Corxel Pharmaceuticals (Shanghai) Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Corxel Pharmaceuticals (Shanghai) Co., Ltd, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cynata Therapeutics Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cynata Therapeutics Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
CytoDyn, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CytoDyn, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Curative Biotechnology, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Curative Biotechnology, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Curacle Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Curacle Co., Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cullinan Oncology LLC Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cullinan Oncology LLC, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Curis, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Curis, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cyclerion Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cyclerion Therapeutics, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Cotinga Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cotinga Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Quince Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Quince Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
CORESTEMCHEMON, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CORESTEMCHEMON, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.